294 related articles for article (PubMed ID: 33790868)
1. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly.
Gil J; Jordà M; Soldevila B; Puig-Domingo M
Front Endocrinol (Lausanne); 2021; 12():646210. PubMed ID: 33790868
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly.
Lekva T; Berg JP; Fougner SL; Olstad OK; Ueland T; Bollerslev J
J Clin Endocrinol Metab; 2012 Aug; 97(8):E1506-14. PubMed ID: 22585092
[TBL] [Abstract][Full Text] [Related]
4. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery.
Lekva T; Berg JP; Heck A; Lyngvi Fougner S; Olstad OK; Ringstad G; Bollerslev J; Ueland T
PLoS One; 2013; 8(6):e66927. PubMed ID: 23825587
[TBL] [Abstract][Full Text] [Related]
5. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.
Gil J; Marques-Pamies M; Valassi E; García-Martínez A; Serra G; Hostalot C; Fajardo-Montañana C; Carrato C; Bernabeu I; Marazuela M; Rodríguez-Lloveras H; Cámara R; Salinas I; Lamas C; Biagetti B; Simó-Servat A; Webb SM; Picó A; Jordà M; Puig-Domingo M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203668
[TBL] [Abstract][Full Text] [Related]
6. The Future of Somatostatin Receptor Ligands in Acromegaly.
Gadelha MR; Wildemberg LE; Kasuki L
J Clin Endocrinol Metab; 2022 Jan; 107(2):297-308. PubMed ID: 34618894
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.
Fleseriu M
Pituitary; 2011 Jun; 14(2):184-93. PubMed ID: 21161602
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin expression is associated with somatostatin analogue response in acromegaly.
Venegas-Moreno E; Flores-Martinez A; Dios E; Vazquez-Borrego MC; Ibañez-Costa A; Madrazo-Atutxa A; Japón MA; Castaño JP; Luque RM; Cano DA; Soto-Moreno A
J Cell Mol Med; 2019 May; 23(5):3088-3096. PubMed ID: 30843342
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression.
Muhammad A; Coopmans EC; Gatto F; Franck SE; Janssen JAMJL; van der Lely AJ; Hofland LJ; Neggers SJCMM
J Clin Endocrinol Metab; 2019 Mar; 104(3):915-924. PubMed ID: 30346538
[TBL] [Abstract][Full Text] [Related]
12. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
13. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
15. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
16. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas.
Gil J; Marques-Pamies M; Jordà M; Fajardo-Montañana C; García-Martínez A; Sampedro M; Serra G; Salinas I; Blanco A; Valassi E; Sesmilo G; Carrato C; Cámara R; Lamas C; Casano-Sancho P; Alvarez CV; Bernabéu I; Webb SM; Picó A; Marazuela M; Puig-Domingo M;
Clin Endocrinol (Oxf); 2021 May; 94(5):811-819. PubMed ID: 32978826
[TBL] [Abstract][Full Text] [Related]
17. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors.
Fuentes-Fayos AC; García-Martínez A; Herrera-Martínez AD; Jiménez-Vacas JM; Vázquez-Borrego MC; Castaño JP; Picó A; Gahete MD; Luque RM
Minerva Endocrinol; 2019 Jun; 44(2):109-128. PubMed ID: 30650942
[TBL] [Abstract][Full Text] [Related]
19. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
20. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
Melmed S; Sternberg R; Cook D; Klibanski A; Chanson P; Bonert V; Vance ML; Rhew D; Kleinberg D; Barkan A
J Clin Endocrinol Metab; 2005 Jul; 90(7):4405-10. PubMed ID: 15827109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
